SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that its patented, cell-directed, extracorporeal Selective Cytopheretic Device (SCD) is being featured in two presentations at the 42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology conference today, June 11, 2024. The International Vicenza Course – a scientific program that integrates industry-sponsored symposia, meet-the-expert sessions and short presentations – is being held June 11-13 in Vicenza, Italy.
DENVER，2024年6月11日(GLOBE NEWSWIRE)——SeaStar醫療控股有限公司(納斯達克: ICU)是一家商業化醫療器械公司，專注於研發自有解決方案以減少高炎症對器官造成的破壞。該公司公佈了其擁有專利的、以電芯爲核心的體外選擇性胞吞吐裝置 (SCD) 受兩場會議的特別關注。42nd個展覽的維琴察AKI-CRRT-ECOS和危重症腎臟病展示SeaStar Medical的SCD技術的演講如下：
"The prestigious International Vicenza Course is known for showcasing breakthroughs in the field of extracorporeal organ support. It is an honor to be invited to showcase our SCD technology by Dr. Claudio Ronco, director of the International Renal Research Institute of Vicenza (IRRIV) and internationally recognized thought leader in the field," said Kevin Chung, MD, SeaStar Medical Chief Medical Officer. "Our SCD offers a groundbreaking approach to treating critically ill pediatric and adult AKI patients. We are excited to share the potential of our therapy to save lives and eliminate dialysis dependency with the audience of global nephrologists and intensivists attending this conference."
SeaStar醫療器械的首席醫療官Kevin Chung博士說：“備受讚譽的國際維琴察課程以展示體外器官支持領域的突破性成果而聞名。 能夠應邀通過國際腎臟研究所的董事Claudio Ronco教授展示我們的SCD技術是一種榮譽。 Claudio Ronco是腎臟研究領域的知名人士，我們的SCD技術爲治療危重症兒科和成人AKI患者提供了開創性的方法。 我們很高興與此次會議的全球腎病學專家和重症監護專家分享我們治療的潛力，以拯救生命並消除透析依賴。”
The presentations featuring SeaStar Medical's SCD are as follows:
A Novel Selective Cytopheretic Device，“由Cincinnati Children's Hospital的Stuart Goldstein醫生主持，他是SeaStar Medical的小兒AKI試驗主要研究員，也是SeaStar Medical科學顧問委員會的成員。該討論將在“小兒CRRT新聞”會議期間舉行，由Cincinnati Children's Hospital和IRRIV共同贊助。
- "A Novel Selective Cytopheretic Device" being presented by Stuart Goldstein, MD, Cincinnati Children's Hospital, principal investigator of SeaStar Medical's pediatric AKI pilot studies and member of SeaStar Medical's Scientific Advisory Board. The discussion will be held during the "News in Pediatric CRRT" session that is jointly sponsored by Cincinnati Children's Hospital and the IRRIV.
- "Cell-directed Therapy: Promising Approach to Sepsis and Other Dysregulated Immunological States, Including Acute Kidney Injury" presented in a SeaStar Medical-sponsored symposium by SCD inventor H. David Humes, MD, Professor, Division of Nephrology, Internal Medicine, University of Michigan and SeaStar Medical Scientific Advisor.
- "細胞定向療法：關於膿毒性休克和其他失調免疫狀態的有前途的方法，包括急性腎損傷“——由SCD發明人H. David Humes博士在SeaStar醫療器械贊助的專題研討會上發表。 他是密歇根大學內科腎臟病學部，分子、細胞和發育生物學系和生物醫學工程中心教授，也是SeaStar Medical的科學顧問。關於第42屆維琴察AKI-CRRT-ECOS和危重症腎病：本屆國際維琴察課程專注於關鍵護理腎病學和相關療法中技術、藥理學、臨床試驗和共識定義的新發展。 會議提供關於科學進步和突破性技術的最新信息，以及基本概念和實用的操作說明。 目標是提高AKI和相關診斷程序以及治療策略（包括新藥物選擇和新的體外治療）的知識和技能。
- "關於選擇性細胞治療設備(SCD)：SCD是一種專利細胞定向體外器件，採用免疫調節技術，在連續腎臟治療（KRT）期間專門針對促炎性中性粒細胞和單核細胞進行選擇性靶向治療，從而減少細胞內的高炎性環境，包括引起炎症，器官衰竭和可能導致死亡的細胞因子風暴。 與病原體清除和其他淨化血液的工具不同，該設備與KRT血液過濾系統集成，以有選擇地靶向並將促炎症單核細胞過渡到修復狀態，並促使激活的中性粒細胞變得不那麼炎症性。 SCD有選擇性地針對最高程度的促炎性中性粒細胞和單核細胞。 然後，將這些細胞回輸到體內通過血液，併發出信號降低其促炎性環境並專注於修復。 這種獨特的免疫調節方法可能促進長期器官恢復，並消除包括透析在內的未來KRT的需要。關於選擇性細胞治療設備(SCD)：SCD是一種專利細胞定向體外器件，採用免疫調節技術，在連續腎臟治療（KRT）期間專門針對促炎性中性粒細胞和單核細胞進行選擇性靶向治療，從而減少細胞內的高炎性環境，包括引起炎症，器官衰竭和可能導致死亡的細胞因子風暴。 與病原體清除和其他淨化血液的工具不同，該設備與KRT血液過濾系統集成，以有選擇地靶向並將促炎症單核細胞過渡到修復狀態，並促使激活的中性粒細胞變得不那麼炎症性。 SCD有選擇性地針對最高程度的促炎性中性粒細胞和單核細胞。 然後，將這些細胞回輸到體內通過血液，併發出信號降低其促炎性環境並專注於修復。 這種獨特的免疫調節方法可能促進長期器官恢復，並消除包括透析在內的未來KRT的需要。
About the 42nd Vicenza Course AKI-CRRT-ECOS and Critical Care Nephrology
The 42nd edition of the International Vicenza Course focuses on new developments in the areas of technology, pharmacology, clinical trials and consensus definitions in critical care nephrology and related therapies. The conference offers the most updated information on scientific advances and breakthrough technologies, together with basic concepts and practical hands-on instructions. The goal is to improve knowledge and skills in AKI and related diagnostic procedures and therapeutic strategies including new pharmacological options and new extracorporeal therapies.
關於第42屆nd個展覽的維琴察AKI-CRRT-ECOS和危重症腎臟病
第42屆展覽的國際維琴察課程側重於關鍵護理腎臟病和相關治療法中技術、藥理學、臨床試驗和共識定義的最新發展。該大會提供有關科學進步和突破技術的最新信息，以及基本概念和實用的操作說明。其目標是提高AKI和相關診斷程序以及治療策略（包括新藥物選擇和新的體外治療）的知識和技能。nd關於選擇性細胞治療設備（SCD）：SCD是一種專利的體外細胞定向設備，採用免疫調節技術，在連續腎臟替代治療（KRT）期間，有針對性地靶向促炎性中性粒細胞和單核細胞，減少細胞內的高炎症環境，包括引發炎症、器官衰竭和可能導致死亡的細胞因子風暴。與清除病原體和淨化血液的其他工具不同，該設備與KRT血液過濾系統集成，有選擇地靶向並將促炎性單核細胞轉變爲修復狀態，並促使激活的中性粒細胞更不具有炎性。SCD有選擇性地靶向最高程度的促炎性中性粒細胞和單核細胞，然後將這些細胞通過血液返還體內，發出信號降低其促炎性環境並專注於修復。 這種獨特的免疫調節方法可能有助於促進長期器官恢復，並消除包括透析在內的未來KRT需求。
About the Selective Cytopheretic Device (SCD)
The SCD is a patented cell-directed extracorporeal device that employs immunomodulating technology to selectively target proinflammatory neutrophils and monocytes during continuous kidney renal therapy (KRT) and reduces the hyperinflammatory milieu including the cytokine storm that causes inflammation, organ failure and possible death in critically ill patients. Unlike pathogen removal and other blood-purification tools, the device is integrated with KRT hemofiltration systems to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. The SCD selectively targets the most highly activated proinflammatory neutrophils and monocytes. These cells are then returned back into the body through the blood, and the body is signaled to lower its inflammatory environment and focus on repair. This unique immunomodulation approach may promote long-term organ recovery and eliminate the need for future KRT, including dialysis.
選擇性細胞治療設備（SCD）：SCD是一種專利的細胞定向體外器件，採用免疫調節技術，在連續腎臟替代治療（KRT）期間專門針對促炎性中性粒細胞和單核細胞進行選擇性靶向治療，從而減少細胞內部高炎症環境，包括引起炎症、器官衰竭和可能導致死亡的細胞因子風暴。與病原體清除和其他淨化血液的工具不同，該設備與KRT血液淨化系統集成，以有選擇地針對並過渡促炎性單核細胞到修復狀態，並促使激活中性粒細胞變得不那麼炎症。SCD有選擇性地針對最高程度的促炎性中性粒細胞和單核細胞。這些單元格會通過血液回輸體內，併發出信號降低其促炎性環境並專注於修復。這種獨特的免疫調節方法可能有助於促進長期器官恢復，並消除對未來KRT（包括透析）的需求。
“關於新穎的選擇性細胞治療設備”，由Cincinnati Children's Hospital的Stuart Goldstein醫生主持，他是SeaStar Medical的小兒AKI試驗主要研究員，也是SeaStar Medical科學顧問委員會的成員。該討論將在“小兒CRRT新聞”會議期間舉行，由Cincinnati Children's Hospital和IRRIV公共贊助。
About SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical's novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
關於SeaStar Medical
SeaStar Medical是商業化醫療技術公司，正在重新定義體外治療如何減少器官過度炎症帶來的後果。SeaStar Medical的新穎技術依靠科技和創新來爲危重病患者提供挽救生命的解決方案。該公司正在開發和商業化的細胞定向體外治療方案針對推動全身性炎症的效應細胞，直接導致組織損傷並分泌一系列促炎性細胞因子，引發和傳播不平衡的免疫反應。欲知詳情請訪問SeaStar Medical網站或訪問我們的。www.seastarmedical.com欲知詳情請訪問SeaStar Medical網站或訪問我們。LinkedIn或。X.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical's expectations with respect to the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical's control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to access funding under existing agreements; (vi) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical's products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical's Annual Report on Form 10-K, including those under the "Risk Factors" section therein and in SeaStar Medical's other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
前瞻性聲明
本新聞稿包含某些前瞻性聲明，屬於1955年《證券訴訟改革法》“安全港”條款所涵蓋的內容。這些前瞻性聲明包括但不限於，SeaStar Medical對SCD治療AKI和其他疾病的能力的期望；商業化預期的監管批准過程和時間表；以及SeaStar Medical符合預期的時間表的能力。本文中的“相信”、“計劃”、“期望”、“預計”、“估計”、“意圖”、“策略”、“未來”、“機遇”、“計劃”、“可能”、“應該”、“將”、“將會”、“將繼續”、“很可能導致”以及類似表述的用詞或短語旨在識別此類前瞻性聲明。前瞻性聲明是對基於當前期望和假設而進行的未來事件的預測、投影和其他陳述，因此受到重大風險和不確定性的影響，這些風險和不確定性可能導致實際結果與預期結果大相徑庭。其中大多數因素超出了SeaStar Medical的控制範圍，難以預測。可能導致實際未來事件與預期結果大相徑庭的因素包括但不限於：（i）SeaStar Medical未能獲得SCD產品候選的監管批准的風險；（ii）SeaStar Medical未能籌集足夠的資本來資助其運營，包括當前或未來的臨床試驗；（iii）SeaStar Medical及其當前和未來的合作伙伴未能成功開發和商業化其產品或服務，或經歷了顯著延遲，包括未能獲得聯邦和州級監管機構批准其產品，（iv）SeaStar Medical可能永遠無法實現或保持盈利能力的風險；（v）SeaStar Medical可能無法根據現有協議獲得資金的風險；（vi）第三方供應商和製造商可能無法充分和及時地履行其義務的風險，（vii）與SeaStar Medical的產品和服務有關的產品責任或監管訴訟或程序的風險，（viii）SeaStar Medical無法獲得或保護其知識產權的風險，以及（ix）SeaStar Medical不時在其年度10-K報告中指出的其他風險和不確定性，包括其中的“風險因素”部分以及SeaStar Medical在SEC的其他申報文件中。上述因素列表並非詳盡無遺。前瞻性聲明僅於其發表日期有效。讀者應謹慎對待前瞻性聲明，並且SeaStar Medical不承擔任何義務也無意更新或修訂這些前瞻性聲明，無論是基於新信息、未來事件還是其他原因。
Investor Contact:
LHA Investor Relations
Jody Cain
(310) 691-7100
Jcain@lhai.com
投資者聯繫人：
投資者關係LHA：
Jody Cain
（310）691-7100
Jcain@lhai.com
# # #
# # #
Source: SeaStar Medical Holding Corporation
消息來源: SeaStar Medical Holding Corporation
譯文內容由第三人軟體翻譯。